Skip to main content

Table 4 Univariate analysis of [68Ga]Ga-DOTA-TOC PET/CT variables for PFS after lanreotide therapy

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

VariableHazard ratio (95% CI)p value
Krenning score (2 and 3 vs. 4 )1.876 (0.713–4.932)0.202
Tumour-to-liver ratio (TLR) (< 8.1 vs. ≥ 8.1)3.329 (1.294–8.561)0.013*
Maximum standardized uptake value (SUVmax) (< 42.94 vs. ≥ 42.94)2.656 (1.059–6.663)0.037*
Whole tumour volume (WTV) (≥ 58.9 cm3 vs. < 58.9 cm3)2.721 (1.100–6.732)0.030*
Total receptor expression (TRE) (≥ 778.5 vs. < 778.5)1.837 (0.0.749–4.506)0.184
  1. *Statistically significant (p < 0.05)